SG11201811230RA - Compositions and methods for reducing ocular neovascularization - Google Patents
Compositions and methods for reducing ocular neovascularizationInfo
- Publication number
- SG11201811230RA SG11201811230RA SG11201811230RA SG11201811230RA SG11201811230RA SG 11201811230R A SG11201811230R A SG 11201811230RA SG 11201811230R A SG11201811230R A SG 11201811230RA SG 11201811230R A SG11201811230R A SG 11201811230RA SG 11201811230R A SG11201811230R A SG 11201811230RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- suite
- pct
- methods
- menlo park
- Prior art date
Links
- 206010029113 Neovascularisation Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 102100022662 Guanylyl cyclase C Human genes 0.000 abstract 1
- 101710198293 Guanylyl cyclase C Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Dispersion Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662351231P | 2016-06-16 | 2016-06-16 | |
| PCT/US2017/038012 WO2017218981A2 (en) | 2016-06-16 | 2017-06-16 | Compositions and methods for reducing ocular neovascularization |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811230RA true SG11201811230RA (en) | 2019-01-30 |
Family
ID=60664289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811230RA SG11201811230RA (en) | 2016-06-16 | 2017-06-16 | Compositions and methods for reducing ocular neovascularization |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20190100582A1 (es) |
| EP (2) | EP3472317B1 (es) |
| JP (3) | JP6990667B2 (es) |
| KR (2) | KR20190038536A (es) |
| AU (2) | AU2017286680B2 (es) |
| CA (1) | CA3027740A1 (es) |
| DK (1) | DK3472317T3 (es) |
| ES (1) | ES2916344T3 (es) |
| HR (1) | HRP20220612T1 (es) |
| HU (1) | HUE059424T2 (es) |
| LT (1) | LT3472317T (es) |
| PL (1) | PL3472317T3 (es) |
| PT (1) | PT3472317T (es) |
| RS (1) | RS63282B1 (es) |
| SG (1) | SG11201811230RA (es) |
| SI (1) | SI3472317T1 (es) |
| WO (1) | WO2017218981A2 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10000741B2 (en) | 2014-03-17 | 2018-06-19 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression in cone cells |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| EP3265178A4 (en) | 2015-03-02 | 2018-09-05 | Adverum Biotechnologies, Inc. | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
| BR112018013407A2 (pt) | 2015-12-30 | 2018-12-18 | Kodiak Sciences Inc | anticorpos e conjugados dos mesmos |
| EP3596213A4 (en) | 2017-03-17 | 2021-02-17 | Adverum Biotechnologies, Inc. | COMPOSITIONS AND PROCEDURES FOR ENHANCED GENE EXPRESSION |
| EA202091509A1 (ru) | 2017-12-19 | 2020-09-22 | Акуос, Инк. | Aav-опосредованная доставка терапевтических антител во внутреннее ухо |
| EP3789489A4 (en) * | 2018-03-30 | 2022-01-05 | Tomoki Todo | SWELLING INHIBITOR-TYPE ONCOLYTIC VIRUS |
| WO2021050094A1 (en) * | 2019-09-11 | 2021-03-18 | Adverum Biotechnologies, Inc. | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
| WO2021071835A1 (en) * | 2019-10-07 | 2021-04-15 | Regenxbio Inc. | Adeno-associated virus vector pharmaceutical composition and methods |
| AU2020364071A1 (en) | 2019-10-10 | 2022-05-26 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2021163451A1 (en) * | 2020-02-14 | 2021-08-19 | Asklepios Biopharmaceutical, Inc. | Method of treating gene therapy associated toxicity with antibiotics |
| CN115869425A (zh) * | 2022-12-12 | 2023-03-31 | 北京生物制品研究所有限责任公司 | 一种aav眼用注射液及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE281469T1 (de) | 1993-03-25 | 2004-11-15 | Merck & Co Inc | Inhibitor des wachstumsfaktors für gefäss- endothelzellen |
| AU2009301141B2 (en) * | 2008-10-07 | 2015-08-27 | Bracco Suisse S.A. | Targeting construct comprising anti-polymer antibody and liposomes or microvesicles binding to the same |
| US8663624B2 (en) * | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| EP3254703B1 (en) * | 2011-04-22 | 2020-02-19 | The Regents of The University of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| TWI775096B (zh) * | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| US10000741B2 (en) * | 2014-03-17 | 2018-06-19 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression in cone cells |
| EP3570895A1 (en) * | 2017-01-17 | 2019-11-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of expressing a polynucleotide of interest in the cone photoreceptors |
-
2017
- 2017-06-16 DK DK17814228.7T patent/DK3472317T3/da active
- 2017-06-16 LT LTEPPCT/US2017/038012T patent/LT3472317T/lt unknown
- 2017-06-16 PL PL17814228.7T patent/PL3472317T3/pl unknown
- 2017-06-16 EP EP17814228.7A patent/EP3472317B1/en active Active
- 2017-06-16 AU AU2017286680A patent/AU2017286680B2/en active Active
- 2017-06-16 KR KR1020197001022A patent/KR20190038536A/ko active IP Right Grant
- 2017-06-16 JP JP2018565844A patent/JP6990667B2/ja active Active
- 2017-06-16 SG SG11201811230RA patent/SG11201811230RA/en unknown
- 2017-06-16 HU HUE17814228A patent/HUE059424T2/hu unknown
- 2017-06-16 WO PCT/US2017/038012 patent/WO2017218981A2/en unknown
- 2017-06-16 EP EP22154859.7A patent/EP4083203A1/en active Pending
- 2017-06-16 PT PT178142287T patent/PT3472317T/pt unknown
- 2017-06-16 HR HRP20220612TT patent/HRP20220612T1/hr unknown
- 2017-06-16 ES ES17814228T patent/ES2916344T3/es active Active
- 2017-06-16 KR KR1020227041433A patent/KR102622823B1/ko active IP Right Grant
- 2017-06-16 SI SI201731153T patent/SI3472317T1/sl unknown
- 2017-06-16 RS RS20220484A patent/RS63282B1/sr unknown
- 2017-06-16 CA CA3027740A patent/CA3027740A1/en active Pending
-
2018
- 2018-12-12 US US16/218,350 patent/US20190100582A1/en not_active Abandoned
-
2021
- 2021-12-06 JP JP2021197648A patent/JP7384447B2/ja active Active
-
2022
- 2022-10-12 US US18/046,112 patent/US20230322911A1/en active Pending
-
2023
- 2023-04-13 AU AU2023202277A patent/AU2023202277A1/en active Pending
- 2023-10-05 JP JP2023173614A patent/JP2023171953A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017286680B2 (en) | 2023-01-19 |
| EP3472317A2 (en) | 2019-04-24 |
| PT3472317T (pt) | 2022-06-27 |
| DK3472317T3 (da) | 2022-05-23 |
| WO2017218981A3 (en) | 2018-02-15 |
| ES2916344T3 (es) | 2022-06-30 |
| HRP20220612T1 (hr) | 2022-07-22 |
| SI3472317T1 (sl) | 2022-08-31 |
| CA3027740A1 (en) | 2017-12-21 |
| JP6990667B2 (ja) | 2022-02-03 |
| JP2023171953A (ja) | 2023-12-05 |
| US20230322911A1 (en) | 2023-10-12 |
| LT3472317T (lt) | 2022-06-27 |
| PL3472317T3 (pl) | 2022-08-08 |
| KR102622823B1 (ko) | 2024-01-10 |
| KR20220162881A (ko) | 2022-12-08 |
| EP3472317B1 (en) | 2022-03-16 |
| JP7384447B2 (ja) | 2023-11-21 |
| JP2022028928A (ja) | 2022-02-16 |
| AU2023202277A1 (en) | 2023-05-11 |
| EP3472317A4 (en) | 2020-02-26 |
| US20190100582A1 (en) | 2019-04-04 |
| KR20190038536A (ko) | 2019-04-08 |
| WO2017218981A2 (en) | 2017-12-21 |
| EP4083203A1 (en) | 2022-11-02 |
| HUE059424T2 (hu) | 2022-11-28 |
| JP2019521989A (ja) | 2019-08-08 |
| RS63282B1 (sr) | 2022-06-30 |
| AU2017286680A1 (en) | 2019-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201903312VA (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201907196YA (en) | Composition and methods for preventing radiation injury and promoting tissue regeneration | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 |